Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1.

Genes to cells : devoted to molecular & cellular mechanisms - 1 Oct 2016

Yoza Kaito, Himeno Rika, Amano Shinjiro, Kobashigawa Yoshihiro, Amemiya Shun, Fukuda Natsuki, Kumeta Hiroyuki, Morioka Hiroshi, Inagaki Fuyuhiko

Abstract excerpt

Over-expression and aberrant activation of tyrosine kinases occur frequently in human cancers. Various tyrosine kinase inhibitors (TKIs) are under clinical use, but acquisition of resistance to these drugs is a major problem. Here, we studied the interaction between two drug-resistant mutants of fibroblast growth factor receptor 1 (FGFR1), N546K and V561M, and four ATP-competitive inhibitors, ponatinib,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Fluorometry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Magnetic Resonance Spectroscopy

Share to Pyridazines

Share to Quinolones

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Spectrometry, Fluorescence

Source

Identifiers

PMID: 27558949
DOI: 10.1111/gtc.12405

Genes

FGFR1
PNP

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1.PMID 27558949Read ↗

Computational biophysical characterization of the effect of gatekeeper mutations on the binding of ponatinib to the FGFR kinase.Semantic proximity Read ↗

Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.Semantic proximity Read ↗

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.Semantic proximity Read ↗

Function and evolution of B-Raf loop dynamics relevant to cancer recurrence under drug inhibition.Semantic proximity Read ↗

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.Semantic proximity Read ↗

Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase InhibitorsSemantic proximity Read ↗

Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistanceSemantic proximity Read ↗

Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state.Semantic proximity Read ↗

Profiling of the drug resistance of thousands of Src tyrosine kinase mutants uncovers a regulatory network that couples autoinhibition to catalytic domain dynamicsSemantic proximity Read ↗

Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.Semantic proximity Read ↗

The D647N mutation of FGFR1 induces ligand-independent receptor activation.Semantic proximity Read ↗

The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.